Press Releases

Date	Title
5/31/23	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/24/23	Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
5/12/23	Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
5/2/23	Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
4/28/23	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/25/23	Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
4/10/23	Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
3/31/23	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/16/23	Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
2/28/23	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IR Menu